Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
She holds a Masters degree in Genetics along with a Ph.D. in Biochemistry
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
Subscribe To Our Newsletter & Stay Updated
